INmune Bio (NASDAQ:INMB) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings raised shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, INmune Bio has a consensus rating of “Moderate Buy”.

INmune Bio Price Performance

Shares of INMB stock opened at $1.13 on Friday. The firm has a market cap of $31.59 million, a PE ratio of -1.88 and a beta of 0.97. The company has a 50-day moving average of $1.88 and a two-hundred day moving average of $1.63. INmune Bio has a 1-year low of $1.06 and a 1-year high of $2.60.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of INmune Bio in the 2nd quarter valued at $35,000. Russell Investments Group Ltd. grew its stake in shares of INmune Bio by 64.0% during the third quarter. Russell Investments Group Ltd. now owns 25,246 shares of the company’s stock worth $49,000 after purchasing an additional 9,850 shares in the last quarter. Focus Partners Advisor Solutions LLC acquired a new position in shares of INmune Bio during the second quarter worth $71,000. Ieq Capital LLC purchased a new position in INmune Bio in the second quarter valued at $134,000. Finally, GSA Capital Partners LLP purchased a new position in INmune Bio in the second quarter valued at $134,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.

Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.